LABORATORY RESEARCH Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer Prostate cancer (PCa) xenografts were examined to identify mechanism of progression after castration and abiraterone. Androgen receptor (AR) reactivation in abiraterone-resistant VCaP xenografts was not associated with restoration of intratumoral androgens or alterations in AR co-regulators. [Clin Cancer Res] Abstract The Role of sLZIP in Cyclin D3-Mediated Negative Regulation of Androgen Receptor Transactivation and Its Involvement in Prostate Cancer Researchers investigated the distinct roles of small leucine zipper protein (sLZIP) in proliferation of androgen-dependent and -independent prostate cancer (PCa) cells. Cyclin D3 is known to interact with androgen receptor (AR) and attenuates the ligand-dependent function of AR in PCa cells. [Oncogene] Abstract Regulation of the Proapoptotic Functions of Prostate Apoptosis Response-4 (Par-4) by Casein Kinase 2 in Prostate Cancer Cells Scientists demonstrated both in rat and humans that Par-4 is a new substrate of the survival kinase casein kinase 2 (CK2) and phosphorylation by CK2 impairs Par-4 proapoptotic functions. They also unravelled different levels of CK2-dependent regulation of Par-4 between species. [Cell Death Dis] Full Article Metastasis of Prostate Cancer and Melanoma Cells in a Preclinical In Vivo Mouse Model Is Enhanced by L-Plastin Expression and Phosphorylation Researchers investigated the relevance of L-plastin expression and phosphorylation by ectopical expression of L-plastin in human melanoma cells and knock-down of endogenous L-plastin in prostate cancer. Knock-down of endogenous L-plastin in human prostate carcinoma cells led to reduced tumor cell growth and metastasis. [Mol Cancer] Full Article Metformin Inhibits Androgen-Induced IGF-IR Upregulation in Prostate Cancer Cells by Disrupting Membrane Initiated Androgen Signaling Scientists evaluated whether Metformin may affect androgen-dependent IGF-IR upregulation. In androgen receptor positive LNCaP prostate cancer cells, they found that Metformin inhibits androgen-induced CRE activity and IGF-IR gene transcription. [Endocrinology] Abstract DNA Damage Response (DDR) via NKX3.1 Expression in Prostate Cells Researchers demonstrated that the DNA damage induced by CPT-11, doxorubicin, and H2O2, but not by etoposide, is negatively influenced by NKX3.1 expression. [J Steroid Biochem Mol Biol] Abstract ERG-SOX4 Interaction Promotes Epithelial-Mesenchymal Transition in Prostate Cancer Cells ERG regulated SOX4 expression via binding to its promoter. Silencing both of them showed duplicate effects on restoring the epithelial characteristics, increasing cellular adhesion and decreasing capacity of cellular migration and invasion. [Prostate] Abstract TUSC3 Loss Alters the ER Stress Response and Accelerates Prostate Cancer Growth In Vivo Scientists provide evidence that tumor suppressor candidate 3 (TUSC3) is part of the oligosaccharyltransferase complex and affects N-linked glycosylation in mammalian cells. Loss of TUSC3 expression in DU145 and PC3 prostate cancer cell lines leads to increased proliferation, migration and invasion as well as accelerated xenograft growth in a PTEN negative background. [Sci Rep] Full Article CLINICAL RESEARCH Genetic Variations in TP53 Binding Sites Are Predictors of Clinical Outcomes in Prostate Cancer Patients Since the tumor protein p53 (TP53), a transcription factor, plays a crucial role in prostate cancer development and progression, we hypothesized that sequence variants in TP53 binding sites might affect clinical outcomes in patients with prostate cancer. We systematically evaluated 41 single nucleotide polymorphisms within genome-wide predicted TP53 binding sites in a cohort of 1,024 prostate cancer patients. [Arch Toxicol] Full Article Enzalutamide after Docetaxel and Abiraterone Therapy in Metastatic Castration-Resistant Prostate Cancer Thirty-five metastatic castration-resistant prostate cancer patients in the German compassionate use program, who received enzalutamide after progression with taxane-based chemotherapy and abiraterone were prospectively evaluated. [Adv Ther] Abstract |